|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||1.23 / 20.32|
The results of the Federal Reserve's June meeting were not a surprise. The central bank left rates unchanged just as Wall Street expected.
Stocks give back gains Wednesday afternoon as Federal Reserve Chair Janet Yellen expresses her confidence in the strength of the U.S. economy.
Aegerion Pharmaceuticals (AEGR) stock is soaring after the company agreed to merge with fellow biopharmaceutical company QLT (QLTI).
Stocks hold gains by mid-morning Wednesday as investors await news on interest rates from the Federal Reserve.
Stock futures signal a Wall Street rebound on Wednesday after four days of losses as investors await news from the Federal Reserve.
Normally, investors get excited when two biotech companies announce a merger. The exception is when the merger is more about desperation than transformation.
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Levi & Korsinsky announces it has commenced an investigation of Aegerion, Inc.
These stocks trading for less than $10 a share look poised to break out and trade higher from current levels.
Investors in Aegerion Pharmaceuticals Inc saw new options begin trading this week, for the May 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AEGR options chain for the new May 20th contracts and identified the following call contract of particular interest.
Trade-Ideas LLC identified Aegerion Pharmaceuticals (AEGR) as a strong on high relative volume candidate
Company Joins NORD, EURORDIS, CORD, The Global Genes Project and Others Worldwide in Supporting Awareness of Rare Diseases
-Company Records Total Net Product Sales of $49.0 Million and $239.9 Million in Fourth Quarter and Full Year of 2015, Respectively-